Jason Bernhard Joins LUNGevity Foundation Board of Directors

WASHINGTON, July 17, 2025 /PRNewswire/ -- LUNGevity Foundation, the leading nonprofit dedicated to changing outcomes for people with lung cancer, proudly announces the appointment of Jason Bernhard, Managing Director and Global Chief Operating Officer of Financial Advisory at Lazard, to its Board of Directors.

With nearly three decades of investment banking experience, Jason has helped healthcare clients navigate complex transactions. His strategic thinking and deep understanding of the healthcare industry will bring powerful insights to LUNGevity's mission to improve outcomes for people impacted by lung cancer.

"We are thrilled to have Jason join the LUNGevity Board," said Andrea Ferris, President and CEO of LUNGevity Foundation. "Jason's investment banking expertise combined with his deep knowledge in the healthcare industry and passion for impact is exactly what we need as we expand our reach and deepen our work across research, care, and advocacy."

Jason's decision to join the Board reflects his personal and professional commitment to advancing solutions in lung cancer. "LUNGevity is doing groundbreaking work that is changing what it means to be diagnosed with lung cancer, and I am honored to join LUNGevity's Board of Directors to help accelerate the organization's efforts to make lung cancer a survivable disease," said Bernhard.

LUNGevity's Board of Directors is a powerhouse of leaders from across sectors — business, medicine, law, and advocacy — all united by a common purpose: to transform lung cancer as we know it and improve outcomes. Jason's appointment further strengthens the Board's strategic depth and capacity to drive impact.

Meet our full Board of Directors 

About LUNGevity Foundation

LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum.

• Through research, we use an innovative and holistic approach to finding lung cancer earlier when it is most treatable; advance research into new treatments so people may live longer and better; and ensure a diverse, vital pipeline of investigators for the future of the lung cancer field.
• Through advocacy, we foster groundbreaking collaborations to ensure all people have access to screening, biomarker testing, and treatment breakthroughs.
• Through community, we educate, support, and connect people affected by lung cancer so that they can get the best healthcare and live longer and better lives.

Comprehensive resources include a medically vetted and patient-centric website, Patient Gateways for specific types of lung cancer, a toll-free HELPLine for personalized support, international survivor conferences, and tools to find a clinical trial. All these programs are designed to help us achieve our vision—a world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

Please visit www.LUNGevity.org to learn more. 

About Lung Cancer in the US

• About 1 in 18 Americans will be diagnosed with lung cancer in their lifetime.
• More than 234,000 people in the US will be diagnosed with lung cancer this year, with a new diagnosis every 2.2 minutes.
• It is estimated that close to 65% of all new lung cancer diagnoses are among people with no tobacco exposure or only past tobacco exposure.
• More lives are lost to lung cancer than to the next two deadliest cancers (colorectal and pancreatic) combined.
• Only 27% of all people diagnosed with lung cancer will survive 5 years or more, but if it's caught before it spreads, the chance of 5-year survival improves to 64%.

SOURCE LUNGevity Foundation